GenSight Biologics Announces its 2023 Financial Calendar

GenSight Biologics announces the drawdown of the first EUR 8 million tranche under its credit agreement with the European Investment Bank

GenSight Biologics Reports Cash Position as of December 31, 2022, FY 2022 Revenues and Provides Business Update

GenSight Biologics secures €12 Million financing through a premium convertible notes issuance to an institutional investor and provides business update

GenSight Biologics secures a €35 million credit facility from the European Investment Bank to support the launch of LUMEVOQ® in Europe

GenSight Biologics Reports Cash Position and Revenues as of September 30, 2022

GenSight Biologics to Present at Upcoming Industry and Investor Conferences

GenSight Biologics Reports Interim Financial Results for the First Half of 2022

GenSight Biologics Announces the Filing of its 2021 Universal Registration Document

GenSight Biologics Reports Cash Position and Revenues as of March 31, 2022